Bank of America’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-15
Closed -$136 6003
2025
Q4
$136 Buy
15
+12
+400% +$21 ﹤0.01% 6766
2025
Q3
$50 Hold
3
﹤0.01% 8007
2025
Q2
$70 Hold
3
﹤0.01% 8037
2025
Q1
$48 Hold
3
﹤0.01% 7990
2024
Q4
$62 Hold
3
﹤0.01% 7831
2024
Q3
$59 Buy
3
+1
+50% +$3 ﹤0.01% 7812
2024
Q2
$37 Buy
+2
New +$6 ﹤0.01% 7899
2023
Q1
Hold
0
-$31 7883
2022
Q4
Hold
0
7895
2022
Q3
Hold
0
7897
2022
Q2
Sell
-18
Closed -$258 8077
2022
Q1
$3K Buy
18
+15
+500% +$361 ﹤0.01% 7973
2021
Q4
$1K Sell
3
-1
-25% -$47 ﹤0.01% 8046
2021
Q3
$2K Sell
4
-39
-91% -$2.55K ﹤0.01% 7876
2021
Q2
$23K Sell
43
-189
-81% -$11.8K ﹤0.01% 7093
2021
Q1
$90K Buy
232
+119
+105% +$8.94K ﹤0.01% 6436
2020
Q4
$48K Buy
113
+41
+57% +$2.79K ﹤0.01% 6341
2020
Q3
$61K Sell
72
-40
-36% -$4.57K ﹤0.01% 5935
2020
Q2
$93K Buy
112
+36
+47% +$3.01K ﹤0.01% 5706
2020
Q1
$28K Sell
76
-14
-16% -$999 ﹤0.01% 6062
2019
Q4
$34K Sell
90
-49
-35% -$4.58K ﹤0.01% 6366
2019
Q3
$236K Sell
139
-93
-40% -$20.1K ﹤0.01% 5560
2019
Q2
$372K Buy
+232
New +$65.7K ﹤0.01% 5261

Other funds holding KRSA

Bank of America's KRSA Position: Q1 2026 in Review

Bank of America sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q1 2026, closing a stake of 15 shares — an estimated $136 sold.

Bank of America first reported a position in KRSA in Q2 2019 and held it in 19 quarters. The position peaked at $372K in Q2 2019. 16 funds tracked by Wall St. Rank hold KRSA as of Q1 2026.

  • Bank of America reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 15 Korsana Biosciences, Inc. Common Stock shares in Q1 2026, an estimated $136.
  • Bank of America first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • Bank of America's Korsana Biosciences, Inc. Common Stock position peaked at $372K in Q2 2019.
  • 16 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.